Skip to main content
64°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S Common Stock
(NY:
NVO
)
69.17
-0.65 (-0.93%)
Official Closing Price
Updated: 5:00 PM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S Common Stock
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
84
85
Next >
What To Expect When IBD 50's No. 2, Hims & Hers, Reports Amid The Semaglutide Battle
February 24, 2025
Hims & Hers Health is on deck to report its fourth-quarter earnings late Monday. Here's what to expect.
Via
Investor's Business Daily
Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
February 24, 2025
Via
The Motley Fool
Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs
February 24, 2025
President Donald Trump has issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the US or face the possibility of tariffs.
Via
Benzinga
Topics
Government
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
February 23, 2025
These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations.
Via
The Motley Fool
ROSEN, A RESPECTED AND LEADING FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO
February 23, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
Why Novo Nordisk Stock Popped on Friday
February 21, 2025
Via
The Motley Fool
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
February 19, 2025
Via
Benzinga
Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes
February 21, 2025
Pfizer has discontinued Beqvez for hemophilia B due to low patient demand and will focus on alternative treatments, including its approved therapy, Hympavzi.
Via
Benzinga
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
February 21, 2025
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage
February 21, 2025
The FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved.
Via
Investor's Business Daily
Digesting Super Bowl Ads, Dunkin' & Starbucks Plans, and Some Weight Loss Drug News
February 19, 2025
The big game didn't live up to the big billing, but there was plenty to take in during commercial breaks and halftime.
Via
The Motley Fool
$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
February 19, 2025
Via
Benzinga
2 Important Insights From Novo Nordisk's Earnings Call
February 16, 2025
Via
The Motley Fool
A Closer Look at Novo Nordisk's Options Market Dynamics
February 14, 2025
Via
Benzinga
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
February 19, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Novo Nordisk Sues Singapore-Based KBP Biosciences Over Alleged Data Misrepresentation In $1.3 Billion Hypertension Drug Deal, Seeks Damages
February 19, 2025
Novo Nordisk sues KBP Biosciences, seeking $830 million in damages over Ocedurenone, alleging data misrepresentation that led to a failed Phase 3 trial.
Via
Benzinga
Topics
Lawsuit
Digging Into What Hershey and Eli Lilly Told Investors
February 19, 2025
Via
The Motley Fool
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
February 18, 2025
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
How Is The Market Feeling About Novo Nordisk?
February 14, 2025
Via
Benzinga
Why Novo Nordisk Stock Keeps Going Down
February 13, 2025
Via
The Motley Fool
3 Hot Stocks That Have Already Doubled in 2025
February 18, 2025
It may be early, but some blazing investments have already delivered wealth-altering gains in this young year.
Via
The Motley Fool
NOVO NORDISK A/S (NYSE: NVO) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
February 18, 2025
From
Bernstein Liebhard LLP
Via
GlobeNewswire
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
February 18, 2025
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Via
Benzinga
These 3 Stocks Just Announced Major Dividend Hikes
February 18, 2025
Via
MarketBeat
Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside
February 17, 2025
Novo Nordisk shares are closing in on a new 52-week low. Is the stock gearing up for a recovery with sentiment currently low?
Via
MarketBeat
NVO STOCK NEWS: NVO Shareholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Novo Nordisk A/S
February 14, 2025
From
Robbins LLP
Via
GlobeNewswire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO
February 14, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
February 14, 2025
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon
February 14, 2025
Via
The Motley Fool
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
February 13, 2025
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.
Via
Benzinga
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
84
85
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.